Investigational drug · Phase 2
NSI-8226
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Asthma.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "NSI-8226"
First trial start
2024
Jul 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NSI-8226", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "NSI-8226" as an intervention, largest first.
- A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic EsophagitisPivotal-lookingActive, not recruiting
Uniquity One (UNI)Industry
NCT06598462 · 184 participants · Start Oct 16, 2024 · Primary completion Apr 30, 2027
Drug: Solrikitug Low Dose; Solrikitug Mid Dose and 1 more · For: Eosinophilic Esophagitis (EoE)
Sites: Dothan, Alabama; Glendale, Arizona; Peoria, Arizona · 73 sites in all
- A Study to Evaluate Solriktug in Adult Participants With AsthmaPivotal-lookingCompleted
Uniquity One (UNI)Industry
NCT06496607 · 145 participants · Start Jul 26, 2024 · Primary completion Jul 6, 2026
Drug: NSI-8226; NSI-8226 and 2 more · For: Asthma
Sites: Mobile, Alabama; Peoria, Arizona; Encinitas, California · 69 sites in all
Uniquity One (UNI)Industry
NCT06640920 · 48 participants · Start Apr 29, 2024 · Primary completion Oct 29, 2024
Drug: Cohort A; Cohort B and 2 more · For: Healthy
Sites: Cincinnati, Ohio
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.